Skip to main content

Advertisement

SpringerLink
Log in

Biomarker beim Prostatakarzinom

Molekulare Ansätze zur Prognoseabschätzung

Biomarkers for prostate cancer

Molecular approaches to assess prognosis

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Obwohl sich das prostataspezifische Antigen (PSA) in der Früherkennung des Prostatakarzinoms als sehr hilfreich erwiesen hat, benötigen wir für das klinische Management von Prostatakarzinompatienten dennoch dringend bessere Biomarker. Sensitivere und spezifischere Biomarker sollen die frühzeitige Diagnose des Prostatakarzinoms präziser und akkurater machen. Darüber hinaus sollen Biomarker genauere Aussagen hinsichtlich der Prognose der Erkrankung und dem Ansprechen auf Therapien machen. Fortschritte der letzten Jahre, insbesondere auf dem Gebiet der Genom- und Proteomanalyse, haben zur Entdeckung viel versprechender Biomarker für das Prostatakarzinom geführt. Dieser Artikel gibt einen Überblick über aktuelle Entwicklungen auf dem Gebiet der Biomarkerforschung beim Prostatakarzinom.

Abstract

Although prostate-specific antigen (PSA) has been shown to be an auxiliary instrument in the management of prostate cancer, there is still an urgent need for better biomarkers. More sensitive and specific biomarkers are needed for a more precise and accurate diagnosis in the early stages of the disease. Furthermore, biomarkers are required for prognostic and predictive purposes. Recent advances in the field of genomics and proteomics have resulted in the identification of promising biomarkers for prostate cancer. This article reviews and discusses several of the most promising candidate biomarkers for prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Perner S, Hofer MD, Kim R et al. (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701

    Article  PubMed  CAS  Google Scholar 

  2. Slovin SF (2005) Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets 9:561–570

    Article  PubMed  CAS  Google Scholar 

  3. Yao D, Trabulsi EJ, Kostakoglu L et al. (2002) The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol 20:211–218

    Article  PubMed  CAS  Google Scholar 

  4. De Marzo AM, Meeker AK, Epstein JI et al. (1998) Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153:911–919

    Google Scholar 

  5. Macri E, Loda M (1998) Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 17:337–344

    Article  PubMed  CAS  Google Scholar 

  6. Lieberfarb ME, Lin M, Lechpammer M et al. (2003) Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res 63:4781–4785

    PubMed  CAS  Google Scholar 

  7. Kuefer R, Hofer MD, Zorn CS et al. (2005) Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer 92:2018–2023

    Article  PubMed  CAS  Google Scholar 

  8. Rubin MA, Gerstein A, Reid K et al. (2000) 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2–3,N+) versus lymph node-negative (pT2–3,N0) prostate cancer. Hum Pathol 31:504–508

    Article  PubMed  CAS  Google Scholar 

  9. Huggins C, Stephens RC, CV H (1941) Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43

  10. Roudier MP, True LD, Higano CS et al. (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34:646–653

    Article  PubMed  Google Scholar 

  11. Dehm SM, Tindall DJ (2005) Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther 5:63–74

    Article  PubMed  CAS  Google Scholar 

  12. Magi-Galluzzi C, Xu X, Hlatky L et al. (1997) Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 10:839–845

    PubMed  CAS  Google Scholar 

  13. Bubendorf L, Kononen J, Koivisto P et al. (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803–806

    PubMed  CAS  Google Scholar 

  14. Reiter RE, Gu Z, Watabe T et al. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 95:1735–1740

    Article  PubMed  CAS  Google Scholar 

  15. Gu Z, Yamashiro J, Kono E et al. (2005) Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 65:9495–9500

    Article  PubMed  CAS  Google Scholar 

  16. Rubin MA, Zhou M, Dhanasekaran SM et al. (2002) alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama 287:1662–1670

    Article  PubMed  CAS  Google Scholar 

  17. Jiang Z, Fanger GR, Woda BA et al. (2003) Expression of alpha-methylacyl-CoA racemase (P504 s) in various malignant neoplasms and normal tissues: astudy of 761 cases. Hum Pathol 34:792–796

    Article  PubMed  CAS  Google Scholar 

  18. Rubin MA, Bismar TA, Andren O et al. (2005) Decreased {alpha}-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 14:1424–1432

    Article  PubMed  CAS  Google Scholar 

  19. Dhanasekaran SM, Barrette TR, Ghosh D et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826

    Article  PubMed  CAS  Google Scholar 

  20. Vasioukhin V (2004) Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 3

  21. Francis NJ, Kingston RE (2001) Mechanisms of transcriptional memory. Nat Rev Mol Cell Biol 2: 409–421

    Article  PubMed  CAS  Google Scholar 

  22. Varambally S, Dhanasekaran SM, Zhou M et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629

    Article  PubMed  CAS  Google Scholar 

  23. Rhodes DR, Sanda MG, Otte AP et al. (2003) Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95:661–668

    Article  PubMed  CAS  Google Scholar 

  24. Rubin MA, Varambally S, Beroukhim R et al. (2004) Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 64:3814–3822

    Article  PubMed  CAS  Google Scholar 

  25. Dhir R, Vietmeier B, Arlotti J et al. (2004) Early identification of individuals with prostate cancer in negative biopsies. J Urol 171:1419–1423

    Article  PubMed  Google Scholar 

  26. Paul B, Dhir R, Landsittel D et al. (2005) Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 65:4097–4100

    Article  PubMed  CAS  Google Scholar 

  27. Bismar TA, Demichelis F, Riva A et al. (2006) Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8:59–68

    Article  PubMed  CAS  Google Scholar 

  28. Tomlins SA, Rhodes DR, Perner S et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648

    Article  PubMed  CAS  Google Scholar 

  29. Perner S, Demichelis F, Beroukhim R et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66:8337–8341

    Article  PubMed  CAS  Google Scholar 

  30. Demichelis F, Fall K, Perner S et al. (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. [Epub ahead of print]

Download references

Interessenkonflikt

Die University of Michigan und das Brigham and Women’s Hospital (Boston) haben ein Patent auf die FISH-Assays zum Nachweis der TMPRSS2-ETS-Genfusionen angemeldet. Die Lizenzrechte zur Entwicklung kommerzieller Tests wurden von der Firma Gen-Probe (San Diego, CA, USA) erworben. Keiner der Autoren ist als Berater für die Firma Gen-Probe tätig.

Author information

Authors and Affiliations

  1. Department of Pathology, Brigham & Women’s Hospital/Harvard Medical School, 221 Longwood Avenue, EBRC 442A, Boston, MA 02115–6110, USA

    S. Perner, K.D. Mertz & M.A. Rubin M.D.

  2. Abt. Pathologie, Universitätsklinikum Ulm, Ulm, Deutschland

    S. Perner

  3. Urologische Universitätsklinik Ulm, Universitätsklinikum Ulm und das Comprehensive Cancer Center Ulm, Ulm, Deutschland

    R. Kuefer

  4. Dana Farber Cancer Institute, Boston, MA, USA

    M.A. Rubin M.D.

  5. Broad Institute of Harvard and the Massachusetts Institute of Technology, Cambridge, MA, USA

    M.A. Rubin M.D.

Authors
  1. S. Perner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K.D. Mertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Kuefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M.A. Rubin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M.A. Rubin M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perner, S., Mertz, K., Kuefer, R. et al. Biomarker beim Prostatakarzinom. Onkologe 13, 669–676 (2007). https://doi.org/10.1007/s00761-007-1225-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-007-1225-9

Schlüsselwörter

Keywords

Search

Navigation